{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:17:10Z","timestamp":1783603030578,"version":"3.55.0"},"reference-count":109,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>HER2-positive breast cancer accounts for approximately 15%\u201320% of breast cancers and was historically associated with poor outcomes. The introduction of HER2-targeted therapies has significantly improved prognosis, particularly in the treatment of early-stage disease. Neoadjuvant HER2-directed therapy combined with chemotherapy is the standard of care for patients with stage II and III HER2-positive breast cancer, enabling pathologic complete response\u2013guided treatment personalization. This review summarizes current evidence guiding the neoadjuvant management of early-stage HER2-positive breast cancer. We discuss pivotal trials establishing dual HER2 blockade with trastuzumab and pertuzumab, strategies to optimize and de-escalate chemotherapy backbones, and emerging data supporting chemotherapy-sparing approaches in selected patients. Recent studies evaluating taxane-only regimens, carboplatin omission, antibody\u2013drug conjugates, and immunotherapy-based combinations are reviewed with attention to efficacy, toxicity, and clinical applicability. We further examine validated and emerging biomarkers of response, including molecular subtyping, genomic assays, tumor immune features, circulating tumor DNA, and functional imaging, all of which may enable risk-adapted treatment strategies. Finally, we review mechanisms of resistance to HER2-targeted therapies, as well as novel therapeutic approaches under investigation to overcome treatment resistance. This review provides a contemporary, evidence-based framework for individualized neoadjuvant treatment of early-stage HER2-positive breast cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2026.7047","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:41:30Z","timestamp":1783600890000},"source":"Crossref","is-referenced-by-count":0,"title":["What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?"],"prefix":"10.6004","volume":"24","author":[{"given":"Daniel S.","family":"Peiffer","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Internal Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Maloney","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Internal Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Nature","first-page":"409","article-title":"Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro","volume":"276","author":"Carpenter G","year":"1978","unstructured":"Carpenter G, King L, Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 1978;276:409\u2013410."},{"key":"B2","series-title":"Cancer Res","first-page":"1463","article-title":"HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes","volume":"76","author":"Nikolai BC","year":"2016","unstructured":"Nikolai BC, Lanz RB, York B,  HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes. Cancer Res 2016;76:1463\u20131475."},{"key":"B3","series-title":"J Clin Oncol","first-page":"5838","article-title":"Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer","volume":"27","author":"Spector NL","year":"2009","unstructured":"Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838\u20135847."},{"key":"B4","series-title":"CA Cancer J Clin","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto AN","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA,  Breast cancer statistics 2024. CA Cancer J Clin 2024;74:477\u2013495."},{"key":"B5","series-title":"Cancer Invest","first-page":"963","article-title":"Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US","volume":"28","author":"Cronin KA","year":"2010","unstructured":"Cronin KA, Harlan LC, Dodd KW,  Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest 2010;28:963\u2013968."},{"key":"B6","series-title":"Nat Rev Mol Cell Biol","first-page":"127","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden Y","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127\u2013137."},{"key":"B7","series-title":"J Clin Oncol","first-page":"3867","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff AC","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M,  Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol 2023;41:3867\u20133872."},{"key":"B8","series-title":"Science","first-page":"177","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon DJ","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG,  Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 1987;235:177\u2013182."},{"key":"B9","series-title":"N Engl J Med","first-page":"122","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz G","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E,  Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377:122\u2013131."},{"key":"B10","series-title":"N Engl J Med","first-page":"783","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon DJ","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S,  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783\u2013792."},{"key":"B11","series-title":"J Clin Oncol","first-page":"3676","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar AU","year":"2005","unstructured":"Buzdar AU, Ibrahim NK, Francis D,  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676\u20133685."},{"key":"B12","series-title":"N Engl J Med","first-page":"724","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain SM","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB,  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724\u2013734."},{"key":"B13","series-title":"Lancet Oncol","first-page":"25","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni L","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH,  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25\u201332."},{"key":"B14","series-title":"JAMA Oncol","first-page":"573","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo HS","year":"2021","unstructured":"Rugo HS, Im SA, Cardoso F,  Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol 2021;7: 573\u2013584."},{"key":"B15","series-title":"J Clin Oncol","first-page":"2610","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: a randomized, phase II study","volume":"37","author":"Ma F","year":"2019","unstructured":"Ma F, Ouyang Q, Li W,  Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: a randomized, phase II study. J Clin Oncol 2019;37:2610\u20132619."},{"key":"B16","series-title":"N Engl J Med","first-page":"597","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy RK","year":"2020","unstructured":"Murthy RK, Loi S, Okines A,  Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020;382:597\u2013609."},{"key":"B17","series-title":"J Clin Oncol","first-page":"3138","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura C","year":"2020","unstructured":"Saura C, Oliveira M, Feng YH,  Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 2020;38:3138\u20133149."},{"key":"B18","article-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3","author":"Gradishar WJ","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J,  NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3 2024. Accessed March 26, 2026. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B19","series-title":"J Cancer Res Clin Oncol","first-page":"1229","article-title":"Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer","volume":"139","author":"Natoli C","year":"2013","unstructured":"Natoli C, Vici P, Sperduti I,  Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. J Cancer Res Clin Oncol 2013;139:1229\u20131240."},{"key":"B20","series-title":"Cancers (Basel)","first-page":"523","article-title":"Neoadjuvant treatment with HER2-targeted therapies in HER2-positive breast cancer: a systematic review and network meta-analysis","volume":"14","author":"Gunasekara ADM","year":"2022","unstructured":"Gunasekara ADM, Anothaisintawee T, Youngkong S,  Neoadjuvant treatment with HER2-targeted therapies in HER2-positive breast cancer: a systematic review and network meta-analysis. Cancers (Basel) 2022; 14:523."},{"key":"B21","series-title":"Chin Clin Oncol","first-page":"32","article-title":"Neoadjuvant treatment for HER2-positive breast cancer","volume":"9","author":"Takada M","year":"2020","unstructured":"Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol 2020;9:32."},{"key":"B22","series-title":"BJS Open","first-page":"zrac028","article-title":"Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis","volume":"6","author":"Davey MG","year":"2022","unstructured":"Davey MG, Browne F, Miller N,  Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis. BJS Open 2022;6:zrac028."},{"key":"B23","series-title":"ESMO Open","first-page":"100433","article-title":"Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials","volume":"7","author":"Guarneri V","year":"2022","unstructured":"Guarneri V, Griguolo G, Miglietta F,  Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. ESMO Open 2022;7:100433."},{"key":"B24","series-title":"Lancet","first-page":"377","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Gianni L","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V,  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377\u2013384."},{"key":"B25","series-title":"Lancet Oncol","first-page":"791","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni L","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH,  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791\u2013800."},{"key":"B26","series-title":"N Engl J Med","first-page":"1673","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond EH","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J,  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673\u20131684."},{"key":"B27","series-title":"J Clin Oncol","first-page":"3744","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez EA","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ,  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014;32:3744\u20133752."},{"key":"B28","series-title":"Breast Cancer Res Treat","first-page":"469","article-title":"Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)","volume":"184","author":"Gonzalez-Santiago S","year":"2020","unstructured":"Gonzalez-Santiago S, Saura C, Ciruelos E,  Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Res Treat 2020;184:469\u2013479."},{"key":"B29","series-title":"Eur J Cancer","first-page":"169","article-title":"Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer","volume":"118","author":"Huober J","year":"2019","unstructured":"Huober J, Holmes E, Baselga J,  Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019;118:169\u2013177."},{"key":"B30","series-title":"Lancet Oncol","first-page":"1183","article-title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","volume":"14","author":"Robidoux A","year":"2013","unstructured":"Robidoux A, Tang G, Rastogi P,  Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1183\u20131192."},{"key":"B31","series-title":"Clin Cancer Res","first-page":"1323","article-title":"Combined perioperative lapatinib and trastuzumab in early HER2-positive breast cancer identifies early responders: randomized UK EPHOS-B trial long-term results","volume":"28","author":"Bundred N","year":"2022","unstructured":"Bundred N, Porta N, Brunt AM,  Combined perioperative lapatinib and trastuzumab in early HER2-positive breast cancer identifies early responders: randomized UK EPHOS-B trial long-term results. Clin Cancer Res 2022;28:1323\u20131334."},{"key":"B32","series-title":"N Engl J Med","first-page":"1273","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon D","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N,  Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273\u20131283."},{"key":"B33","series-title":"J Clin Oncol","first-page":"1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman A","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK,  Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215\u20131221."},{"key":"B34","series-title":"Ann Oncol","first-page":"2278","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss A","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T,  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278\u20132284."},{"key":"B35","series-title":"Lancet Oncol","first-page":"1630","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst MS","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED,  Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19:1630\u20131640."},{"key":"B36","series-title":"JAMA Oncol","first-page":"978","article-title":"Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial","volume":"7","author":"van der Voort A","year":"2021","unstructured":"van der Voort A, van Ramshorst MS, van Werkhoven ED,  Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol 2021;7:978\u2013984."},{"key":"B37","series-title":"J Clin Oncol","first-page":"Abstract 501","article-title":"Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial","volume":"43","author":"Tung NM","year":"2025","unstructured":"Tung NM, Zhao F, DeMichele A,  Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial. J Clin Oncol 2025;43(Suppl):Abstract 501."},{"key":"B38","series-title":"J Clin Oncol.","article-title":"Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2-positive breast cancer: the randomized noninferiority phase III neoCARHP trial","author":"Gao HF","year":"2026","unstructured":"Gao HF, Ye GL, Lin Y,  Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2-positive breast cancer: the randomized noninferiority phase III neoCARHP trial. J Clin Oncol. Published online January 23, 2026. doi:10.1200\/JCO-25-02176"},{"key":"B39","series-title":"Lancet Oncol","first-page":"545","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac A","year":"2017","unstructured":"Llombart-Cussac A, Cortes J, Pare L,  HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol 2017;18:545\u2013554."},{"key":"B40","series-title":"Ann Oncol","first-page":"2768","article-title":"De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +\/- weekly paclitaxel","volume":"28","author":"Nitz UA","year":"2017","unstructured":"Nitz UA, Gluz O, Christgen M,  De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +\/- weekly paclitaxel. Ann Oncol 2017;28:2768\u20132772."},{"key":"B41","series-title":"J Clin Oncol","first-page":"1726","article-title":"Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2\u2013overexpressing breast cancer: TBCRC 006","volume":"31","author":"Rimawi MF","year":"2013","unstructured":"Rimawi MF, Mayer IA, Forero A,  Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2\u2013overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013;31:1726\u20131731."},{"key":"B42","article-title":"PHERGain-2: a phase II study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive low-risk early breast cancer","author":"Llombart-Cussac A","year":"2026","unstructured":"Llombart-Cussac A. PHERGain-2: a phase II study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive low-risk early breast cancer. Presented at ESMO Breast Cancer 2026; May 6\u20138, 2026; Berlin, Germany."},{"key":"B43","series-title":"Lancet Oncol","first-page":"629","article-title":"Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial","volume":"26","author":"Kuemmel S","year":"2025","unstructured":"Kuemmel S, Graeser M, Schmid P,  Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol 2025;26:629\u2013640."},{"key":"B44","series-title":"Cancer Res","first-page":"Abstract CT029","article-title":"Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: a prospective, open-label phase II trial","volume":"84","author":"Guan J","year":"2024","unstructured":"Guan J, Sun K, Jain D,  Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: a prospective, open-label phase II trial. Cancer Res 2024;84(Suppl): Abstract CT029."},{"key":"B45","series-title":"Nat Rev Clin Oncol","first-page":"327","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago JZ","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 2021;18:327\u2013344."},{"key":"B46","series-title":"MAbs","first-page":"2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker H","year":"2023","unstructured":"Maecker H, Jonnalagadda V, Bhakta S,  Exploration of the antibody-drug conjugate clinical landscape. MAbs 2023;15:2229101."},{"key":"B47","series-title":"Cancer Discov","first-page":"2089","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo R","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR,  The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov 2024;14:2089\u20132108."},{"key":"B48","series-title":"Lancet Oncol","first-page":"732","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Dieras V","year":"2017","unstructured":"Dieras V, Miles D, Verma S,  Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:732\u2013742."},{"key":"B49","series-title":"N Engl J Med","first-page":"249","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer CE","year":"2025","unstructured":"Geyer CE, Untch M, Huang CS,  Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med 2025;392:249\u2013257."},{"key":"B50","series-title":"Nat Med","first-page":"2208","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cortes J","year":"2024","unstructured":"Cortes J, Hurvitz SA, Im SA,  Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med 2024;30:2208\u20132215."},{"key":"B51","series-title":"Lancet Oncol","first-page":"115","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz SA","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF,  Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2018;19:115\u2013126."},{"key":"B52","series-title":"Breast Cancer Res","first-page":"2.","article-title":"Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)","volume":"25","author":"de Haas SL","year":"2023","unstructured":"de Haas SL, Slamon DJ, Martin M,  Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res 2023;25:2."},{"key":"B53","series-title":"Breast Cancer Res Treat","first-page":"447","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou Y","year":"2017","unstructured":"Hou Y, Nitta H, Wei L,  HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat 2017;166:447\u2013457."},{"key":"B54","series-title":"Cancer Sci","first-page":"1039","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani Y","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M,  Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 2016;107:1039\u20131046."},{"key":"B55","series-title":"N Engl J Med","first-page":"845","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl S","year":"2026","unstructured":"Loibl S, Park YH, Shao Z,  Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med 2026;394:845\u2013857."},{"key":"B56","series-title":"Ann Oncol","first-page":"166","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck N","year":"2026","unstructured":"Harbeck N, Modi S, Pusztai L,  Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol 2026;37:166\u2013179."},{"key":"B57","series-title":"Int J Cancer","first-page":"844","article-title":"Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer","volume":"142","author":"Zhao B","year":"2018","unstructured":"Zhao B, Zhao H. Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer. Int J Cancer 2018;142:844\u2013853."},{"key":"B58","series-title":"Cancer Treat Rev","first-page":"101965","article-title":"HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis","volume":"84","author":"Schettini F","year":"2020","unstructured":"Schettini F, Pascual T, Conte B,  HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev 2020;84:101965."},{"key":"B59","series-title":"JAMA Oncol","first-page":"603","article-title":"Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2\/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials","volume":"10","author":"Fernandez-Martinez A","year":"2024","unstructured":"Fernandez-Martinez A, Rediti M, Tang G,  Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2\/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA Oncol 2024;10:603\u2013611."},{"key":"B60","series-title":"EBioMedicine","first-page":"103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat A","year":"2022","unstructured":"Prat A, Guarneri V, Pascual T,  Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine 2022;75:103801."},{"key":"B61","series-title":"Clin Cancer Res","first-page":"4123","article-title":"HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from the PHERGain phase II trial","volume":"30","author":"Llombart-Cussac A","year":"2024","unstructured":"Llombart-Cussac A, Perez-Garcia J, Braso-Maristany F,  HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from the PHERGain phase II trial. Clin Cancer Res 2024;30:4123\u20134130."},{"key":"B62","series-title":"EBioMedicine","first-page":"104320","article-title":"HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial","volume":"85","author":"Guarneri V","year":"2022","unstructured":"Guarneri V, Bras-Maristany F, Dieci MV,  HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial. EBioMedicine 2022;85:104320."},{"key":"B63","series-title":"JAMA Oncol","first-page":"835","article-title":"Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab","volume":"9","author":"Waks AG","year":"2023","unstructured":"Waks AG, Ogayo ER, Pare L,  Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab. JAMA Oncol 2023;9:835\u2013840."},{"key":"B64","series-title":"Lancet Oncol","first-page":"1100","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis","volume":"26","author":"Villacampa G","year":"2025","unstructured":"Villacampa G, Pascual T, Tarantino P,  HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Lancet Oncol 2025;26:1100\u20131112."},{"key":"B65","series-title":"ESMO Real World Data Digit Oncol","first-page":"100123","article-title":"Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study","volume":"8","author":"Mart\u00ednez-S\u00e1ez O","year":"2025","unstructured":"Mart\u00ednez-S\u00e1ez O, Tapia M, Mar\u00edn-Aguilera M,  Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study. ESMO Real World Data Digit Oncol 2025;8:100123."},{"key":"B66","series-title":"Lancet Oncol","first-page":"40","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert C","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S,  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018;19:40\u201350."},{"key":"B67","series-title":"Ann Oncol","first-page":"1867","article-title":"Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial","volume":"27","author":"Dieci MV","year":"2016","unstructured":"Dieci MV, Prat A, Tagliafico E,  Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol 2016;27:1867\u20131873."},{"key":"B68","series-title":"Ann Oncol","first-page":"259","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado R","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S,  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26:259\u2013271."},{"key":"B69","series-title":"J Clin Oncol","first-page":"4184","article-title":"Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer","volume":"38","author":"Fernandez-Martinez A","year":"2020","unstructured":"Fernandez-Martinez A, Krop IE, Hillman DW,  Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. J Clin Oncol 2020;38:4184\u20134193."},{"key":"B70","series-title":"JAMA Oncol","first-page":"490","article-title":"Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2\/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials","volume":"9","author":"Fernandez-Martinez A","year":"2023","unstructured":"Fernandez-Martinez A, Pascual T, Singh B,  Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2\/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol 2023;9:490\u2013499."},{"key":"B71","series-title":"JAMA Oncol","first-page":"227","article-title":"RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial","volume":"3","author":"Fumagalli D","year":"2017","unstructured":"Fumagalli D, Venet D, Ignatiadis M,  RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol 2017;3:227\u2013234."},{"key":"B72","series-title":"Clin Cancer Res","first-page":"3581","article-title":"Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial","volume":"25","author":"Rothe F","year":"2019","unstructured":"Rothe F, Silva MJ, Venet D,  Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial. Clin Cancer Res 2019;25:3581\u20133588."},{"key":"B73","series-title":"Clin Cancer Res","first-page":"5384","article-title":"Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant \u201cGeparquattro\u201d trial","volume":"23","author":"Riethdorf S","year":"2017","unstructured":"Riethdorf S, Muller V, Loibl S,  Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant \u201cGeparquattro\u201d trial. Clin Cancer Res 2017;23:5384\u20135393."},{"key":"B74","series-title":"Ann Oncol","first-page":"229","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua MJM","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT,  Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol 2021;32:229\u2013239."},{"key":"B75","series-title":"J Nucl Med","first-page":"1862","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO","volume":"54","author":"Gebhart G","year":"2013","unstructured":"Gebhart G, Gamez C, Holmes E,  18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med 2013;54:1862\u20131868."},{"key":"B76","series-title":"Lancet Oncol","first-page":"858","article-title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"Perez-Garcia JM","year":"2021","unstructured":"Perez-Garcia JM, Gebhart G, Ruiz Borrego M,  Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol 2021;22:858\u2013871."},{"key":"B77","series-title":"JAMA Oncol","first-page":"1360","article-title":"Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial","volume":"7","author":"Hatschek T","year":"2021","unstructured":"Hatschek T, Foukakis T, Bjohle J,  Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial. JAMA Oncol 2021;7:1360\u20131367."},{"key":"B78","series-title":"J Nucl Med","first-page":"1690","article-title":"Correlation of SUV on early interim PET with recurrence-free survival and overall survival in primary operable HER2-positive breast cancer (the TBCRC026 trial)","volume":"64","author":"Hennessy MA","year":"2023","unstructured":"Hennessy MA, Leal JP, Huang CY,  Correlation of SUV on early interim PET with recurrence-free survival and overall survival in primary operable HER2-positive breast cancer (the TBCRC026 trial). J Nucl Med 2023;64:1690\u20131696."},{"key":"B79","series-title":"Lancet Oncol","first-page":"603","article-title":"MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study","volume":"25","author":"van der Voort A","year":"2024","unstructured":"van der Voort A, Louis FM, van Ramshorst MS,  MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. Lancet Oncol 2024;25:603\u2013613."},{"key":"B80","series-title":"J Clin Oncol","first-page":"LBA1008","article-title":"Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): Interim results from DESTINY-Breast09","volume":"43","author":"Tolaney SM","year":"2025","unstructured":"Tolaney SM, Jiang Z, Zhang Q,  Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): Interim results from DESTINY-Breast09. J Clin Oncol 2025;43(Suppl):LBA1008."},{"key":"B81","series-title":"Cancers (Basel)","first-page":"2126","article-title":"High HER2 intratumoral heterogeneity is resistant to anti-HER2 neoadjuvant chemotherapy in early stage and locally advanced HER2-positive breast cancer","volume":"17","author":"Hatano T","year":"2025","unstructured":"Hatano T, Tanei T, Seno S,  High HER2 intratumoral heterogeneity is resistant to anti-HER2 neoadjuvant chemotherapy in early stage and locally advanced HER2-positive breast cancer. Cancers (Basel) 2025;17:2126."},{"key":"B82","series-title":"Breast","first-page":"136","article-title":"Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer","volume":"61","author":"Nakajima H","year":"2022","unstructured":"Nakajima H, Harano K, Nakai T,  Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. Breast 2022;61:136\u2013144."},{"key":"B83","series-title":"Cancer Discov","first-page":"235","article-title":"Trastuzumab deruxtecan (T-DXd) resistance via loss of HER2 expression and binding","volume":"16","author":"Chen W","year":"2026","unstructured":"Chen W, Gupta A, Mai N,  Trastuzumab deruxtecan (T-DXd) resistance via loss of HER2 expression and binding. Cancer Discov 2026;16:235\u2013249."},{"key":"B84","series-title":"Ann Oncol","first-page":"S123","article-title":"LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial","volume":"33","author":"Mosele MF","year":"2022","unstructured":"Mosele MF, Lusque A, Dieras V,  LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial. Ann Oncol 2022;33:S123."},{"key":"B85","series-title":"Am J Clin Pathol","first-page":"755","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee HJ","year":"2014","unstructured":"Lee HJ, Seo AN, Kim EJ,  HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol 2014;142:755\u2013766."},{"key":"B86","series-title":"Cancer Discov","first-page":"2474","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho OM","year":"2021","unstructured":"Filho OM, Viale G, Stein S,  Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov 2021;11:2474\u20132487."},{"key":"B87","series-title":"Cancer Res Commun","first-page":"1927","article-title":"HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer","volume":"3","author":"Olson D","year":"2023","unstructured":"Olson D, Taylor J, Willis K,  HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer. Cancer Res Commun 2023;3:1927\u20131939."},{"key":"B88","series-title":"Sci Rep","first-page":"16964","article-title":"Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer","volume":"15","author":"Zidel A","year":"2025","unstructured":"Zidel A, Benton A, Brown E,  Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. Sci Rep 2025;15:16964."},{"key":"B89","series-title":"Front Oncol","first-page":"1041111","article-title":"The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: a real-world study","volume":"13","author":"Li F","year":"2023","unstructured":"Li F, Liang Y, Luo M,  The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: a real-world study. Front Oncol 2023;13:1041111."},{"key":"B90","series-title":"Ther Adv Med Oncol","first-page":"17588359251379392","article-title":"A phase Ib\/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive\/HER2-negative inflammatory breast cancer (including stage III and IV disease)","volume":"17","author":"Lim B","year":"2025","unstructured":"Lim B, Marx A, Kai M,  A phase Ib\/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive\/HER2-negative inflammatory breast cancer (including stage III and IV disease). Ther Adv Med Oncol 2025;17:17588359251379392."},{"key":"B91","series-title":"Br J Cancer","first-page":"103","article-title":"Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer","volume":"112","author":"Lee HJ","year":"2015","unstructured":"Lee HJ, Seo AN, Kim EJ,  Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer 2015;112:103\u2013111."},{"key":"B92","series-title":"Cell Rep Med","first-page":"101792","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta A","year":"2024","unstructured":"Gupta A, Michelini F, Shao H,  EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med 2024;5:101792."},{"key":"B93","series-title":"Breast Cancer Res Treat","first-page":"685","article-title":"EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance","volume":"122","author":"Dua R","year":"2010","unstructured":"Dua R, Zhang J, Nhonthachit P,  EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 2010;122:685\u2013697."},{"key":"B94","series-title":"Br J Cancer","first-page":"1065","article-title":"EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial","volume":"111","author":"Cheng H","year":"2014","unstructured":"Cheng H, Ballman K, Vassilakopoulou M,  EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer 2014;111:1065\u20131071."},{"key":"B95","series-title":"Lancet","first-page":"633","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga J","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H,  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633\u2013640."},{"key":"B96","series-title":"Clin Cancer Res","first-page":"6277","article-title":"A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer","volume":"14","author":"Arteaga CL","year":"2008","unstructured":"Arteaga CL, O\u2019Neill A, Moulder SL,  A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008;14:6277\u20136283."},{"key":"B97","series-title":"Clin Breast Cancer","first-page":"16","article-title":"A phase I\/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach","volume":"9","author":"Britten CD","year":"2009","unstructured":"Britten CD, Finn RS, Bosserman LD,  A phase I\/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer 2009;9:16\u201322."},{"key":"B98","series-title":"Cancer Res Treat.","article-title":"HER3 expression and PIK3CA mutational status predict pathological response of neoadjuvant therapy in HER2 positive breast cancer patients","author":"Xia X","year":"2025","unstructured":"Xia X, Zong Z, Shen J,  HER3 expression and PIK3CA mutational status predict pathological response of neoadjuvant therapy in HER2 positive breast cancer patients. Cancer Res Treat. Published online July 2, 2025. doi:10.4143\/crt.2025.242"},{"key":"B99","series-title":"J Transl Med","first-page":"665","article-title":"HER3 receptor and its role in the therapeutic management of metastatic breast cancer","volume":"22","author":"Zhu M","year":"2024","unstructured":"Zhu M, Yu M, Meng Y,  HER3 receptor and its role in the therapeutic management of metastatic breast cancer. J Transl Med 2024;22:665."},{"key":"B100","series-title":"Mol Cancer","first-page":"134","article-title":"The anti-erbB3 antibody MM-121\/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells","volume":"12","author":"Huang J","year":"2013","unstructured":"Huang J, Wang S, Lyu H,  The anti-erbB3 antibody MM-121\/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer 2013;12:134."},{"key":"B101","series-title":"Future Oncol","first-page":"1057","article-title":"The phase I\/II eNRGy trial: zenocutuzumab in patients with cancers harboring NRG1 gene fusions","volume":"20","author":"Kim DW","year":"2024","unstructured":"Kim DW, Schram AM, Hollebecque A,  The phase I\/II eNRGy trial: zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol 2024;20:1057\u20131067."},{"key":"B102","series-title":"NPJ Precis Oncol","first-page":"262","article-title":"Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors","volume":"9","author":"Xiang S","year":"2025","unstructured":"Xiang S, Zheng Y, Wang M,  Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors. NPJ Precis Oncol 2025;9:262."},{"key":"B103","series-title":"Sci Rep","first-page":"21762","article-title":"Combination treatment with a PI3K\/Akt\/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells","volume":"10","author":"Fujimoto Y","year":"2020","unstructured":"Fujimoto Y, Morita TY, Ohashi A,  Combination treatment with a PI3K\/Akt\/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep 2020;10:21762."},{"key":"B104","series-title":"J Clin Oncol","first-page":"1059","article-title":"MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and\/or hormone receptor-negative breast cancers in the I-SPY 2 trial","volume":"38","author":"Chien AJ","year":"2020","unstructured":"Chien AJ, Tripathy D, Albain KS,  MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and\/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol 2020;38:1059\u20131069."},{"key":"B105","series-title":"NPJ Breast Cancer","first-page":"48","article-title":"Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial","volume":"6","author":"Wolf DM","year":"2020","unstructured":"Wolf DM, Yau C, Wulfkuhle J,  Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. NPJ Breast Cancer 2020;6:48."},{"key":"B106","series-title":"Cancer Cell","first-page":"395","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns K","year":"2007","unstructured":"Berns K, Horlings HM, Hennessy BT,  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395\u2013402."},{"key":"B107","series-title":"Br J Cancer","first-page":"1367","article-title":"Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas","volume":"106","author":"Gallardo A","year":"2012","unstructured":"Gallardo A, Lerma E, Escuin D,  Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 2012;106:1367\u20131373."},{"key":"B108","series-title":"Breast Cancer Res Treat","first-page":"731","article-title":"Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer","volume":"167","author":"Rimawi MF","year":"2018","unstructured":"Rimawi MF, De Angelis C, Contreras A,  Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 2018;167:731\u2013740."},{"key":"B109","series-title":"Ann Oncol","first-page":"S627","article-title":"200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +\/- the PI3K inhibitor inavolisib in patients (pts) with HER2+\/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa","volume":"33","author":"Loibl S","year":"2022","unstructured":"Loibl S, Reinisch M, Denkert C,  200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +\/- the PI3K inhibitor inavolisib in patients (pts) with HER2+\/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa. Ann Oncol 2022;33:S627."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e267047.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e267047.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e267047.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:41:30Z","timestamp":1783600890000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e267047.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":109,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7047","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}